Anavex Life Sciences Corp (AVXL)

[nidan7500]

With the full changeout of upper level management with the departure of the CFO, the new crew under Vournatsos has very little allegiance to the current pipeline including Aducanumab and its very costly P3. Their new Head of R&D, Micheal Ehler's statement about "acquiring drugs before they've been completely proven." is quite telling. Pressure will continue from Biogen's BOD for the Management Team to stop the bleeding.

T-38-agree with your thought process. Could it be they see the new FDA and new refined/precision medicine brings a level of certainty to new products approvals. How bout more/better process information and tuning as we go vs bet the farm-do or die or pass-fail or get a bigger sample thinking? BTD is the prize for the right answer the first time.